Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: Venture Capital Firm Partners With Hospitals to Launch New Medical Technologies

31 Oct

A Venture Capital firm specializing in technologies, financials and healthcare industries has an investment management team that includes many experts and experienced professionals from hospitals and healthcare systems.  The firm has partnered with premier hospitals in the US, Taiwan and China to introduce new technologies.

The investment strategy of the firm has three main sectors: Greater China’s healthcare reform opportunities, disruptive medical technologies & business models, and synergies with their domestic and foreign hospital & medical network.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Global Technology Corporation Invests in Software-Enabled Devices

31 Oct

The healthcare and life sciences branch of a global technology corporation and manufacturing company looks to invest primarily in Series A or later companies in digital health, medical devices, genomics and molecular diagnostics technologies, but can expand their focus conditionally. While some of their investments are strategic to the parent company, the firm is willing to invest outside of corporate strategic areas. The firm is a global investor, and can act as both a strategic partner and a financial investor, depending on the company.

The firm can invest as a strategic manufacturing company, but is also interested in software-enabled technologies and connected devices. While the firm may consider PMA devices, most investments are in 510k-pathway products. For purely digital health products, such as IoT technology, the firm would like to see some revenue and market traction before investing. For both medical devices and digital health, the firm is agnostic to indication. Firm’s interest in genomics and molecular diagnostics primarily relate to the oncology space, and prefer to see technologies with some clinical data.

The firm may take a board seat after investing, if they are the lead or if they have strategic value to offer the portfolio company, but will generally not take a board seat if they are co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Japan Private Equity Looking Globally for Therapeutics, Devices and Digital Medicine

31 Oct

A private equity firm based in Japan makes venture stage investments, with  a typical investment size of USD 3-5 million per company. The firm’s geographical focus is Asia, centered on Japan and Taiwan. However, the firm may consider companies in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm will primarily focus on therapeutics, and is also interested in medical devices and digital medicine. The firm is interested in new technologies such as cell and gene therapies, but also considers investing in small molecules and biologics, as well as biosimilars and reformulated drugs. The firm will invest in any indication area. The firm invests in companies from the late preclinical stage through to Phase II.

The firm is usually a follow-on investor. For early stage opportunities, the firm prefers that the company has a clinical trial plan in place. While the firm is interested in international opportunities, they prefer that the company is interested in expanding into Japan or Taiwan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: